Hypertension Part 2 | Harrison Simplified

Описание: This video provides a comprehensive and structured overview of hypertension management, based on Harrison’s Principles of Internal Medicine, 22nd edition.

⚠️ Important note:
This is a detailed and in-depth management video. It is recommended to watch it once carefully to build a strong conceptual understanding of hypertension management.
A separate summary/revision video will be prepared later for quick review.

00:00 – 01:06 | Introduction & Core Management
01:07 – 03:04 | Diagnostic Criteria & Staging of Hypertension

🧘 Non-Pharmacological Management
03:05 – 06:08 | Overview of Lifestyle Interventions
03:21 – 03:58 | DASH Diet
04:00 – 04:20 | Weight Loss
04:22 – 04:49 | Salt Restriction
05:00 – 05:31 | Potassium Supplementation
05:33 – 05:59 | Physical Activity
06:00 – 06:08 | Alcohol Reduction
06:09 – 06:47 | Synergy of Lifestyle Changes & Clinical Application

📜 Background & Evidence
06:48 – 08:48 | Historical Context of Hypertension Treatment
08:49 – 10:04 | Meta-analysis Data & Treatment Benefits

💊 Pharmacological Therapy
10:05 – 11:27 | Five Core Classes of Antihypertensive Drugs

Diuretics
11:28 – 13:55 | Thiazide & Thiazide-like Diuretics
12:00 – 13:20 | Chlorthalidone vs HCTZ
13:21 – 13:55 | Adverse Effects

RAAS Blockers (ACEi & ARBs)
13:56 – 16:40 | Clinical Use & Safety
14:16 – 14:38 | Mechanism of Action
15:25 – 15:53 | ACE Inhibitor–Induced Cough
15:55 – 16:40 | Safety Warnings

Calcium Channel Blockers

16:41 – 18:13 | CCBs Overview
17:08 – 17:59 | Dihydropyridines (DHPs)
18:00 – 18:13 | Non-Dihydropyridines

Beta Blockers

19:26 – 21:11 | Role in Hypertension
19:35 – 20:05 | Why Beta-Blockers Are Inferior as First-Line
20:06 – 20:45 | Generations of Beta-Blockers
20:51 – 21:11 | Specific Clinical Indications

🔗 Treatment Strategy
21:12 – 23:19 | Combination Therapy Approach
21:48 – 22:30 | Initial Treatment Selection
22:31 – 22:50 | Minimizing Side Effects
22:51 – 23:19 | Best Drug Combinations
23:21 – 23:42 | Single-Pill Combinations
23:43 – 24:09 | Expected Number of Drugs to Reach Goal
24:10 – 24:58 | Therapeutic Inertia

🎯 Blood Pressure Targets

24:59 – 26:40 | Ideal BP Goals & Evidence (SPRINT Trial)
Earlier editions of Harrison highlighted concerns about excessive blood pressure lowering suggesting a potential increase in cardiovascular risk with very low BP—especially low diastolic pressure. However, recent randomized trials, most notably the SPRINT trial, demonstrated that intensive systolic BP control improves cardiovascular outcomes and reduces mortality, provided diastolic hypotension is avoided.
Current guidelines therefore recommend a target blood pressure of less than 130/80 mmHg for most patients.

👥 Special Populations
26:41 – 35:59 | Hypertension in Special Populations
26:52 – 27:29 | Cardiovascular Disease (CAD, HF, Stroke)
27:30 – 28:49 | Diabetes Mellitus
28:50 – 31:23 | Chronic Kidney Disease (CKD)
31:24 – 33:34 | Elderly Patients
33:35 – 35:17 | Non-Hispanic Black Adults
35:18 – 35:59 | Sex Differences

🚨 Resistant Hypertension

36:00 – 37:34 | Resistant Hypertension
36:07 – 36:23 | Definition
36:24 – 37:34 | Ruling Out Pseudo-Resistance

🎯 Target audience:
Medical students, interns, residents, and clinicians seeking a clear, logical, and exam-relevant approach to hypertension management.

💬 Feel free to leave questions or topic requests in the comments
.
PDF SLIDES
https://drive.google.com/file/d/1DxxJ...